Acute Radiation Syndrome - Pipeline Insight, 2020

Publisher Name :
Date: 24-Nov-2020
No. of pages: 60
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "Acute Radiation Syndrome - Pipeline Insight, 2020," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Acute Radiation Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

Acute Radiation Syndrome Understanding

Acute Radiation Syndrome: Overview

Acute Radiation Syndrome (ARS) also known as radiation toxicity or radiation sickness is an illness when a person's whole body or a significant portion of body is exposed to high levels of radiation for a short period of time. The amount of radiation that a person's body absorbs is called the radiation dose. The major cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Types of radiation that can cause ARS include alpha radiation particles, beta radiation particles - charged particles (electrons), gamma rays, x-rays, neutrons etc.

Symptoms

The effects of exposure to radiations are nonspecific signs and symptoms such as nausea, emesis, fatigue, fever, Diarrhea, Headache, Dizziness and disorientation, Hair loss, Bloody vomit and stools from internal bleeding, low blood pressure and anorexia. The severity of symptoms depends on how much radiation was absorbed, the strength of the radiated energy, the time of exposure, and the distance between body and the source of radiation. The severity of radiation sickness also depends on sensitivity of the affected tissue like the gastrointestinal system and bone marrow are highly sensitive to radiation.

Diagnosis

A diagnosis of Acute Radiation Syndrome without any history of exposure to radiation is complicated as the symptoms are nonspecific. The quickest and easiest laboratory test to provide an estimate of exposure is by measuring an absolute lymphocyte count is. Cytogenetic dosimetry, the gold standard, relies on predictable and standardized effects of radiation on deoxyribonucleic acid (DNA) replication in cultured lymphocytes.

Treatment

Treatment of Acute Radiation Syndrome (ARS) focuses on reducing and treating infections, maintaining hydration, and treating injuries and burns, surgery for patients with life threatening disease. Some patients may benefit from treatments that help the bone marrow recover its function. Supportive care saves lives when it comes to acute radiation syndrome. The lower the radiation dose, the more likely it is that the person will recover from ARS. For survivors of ARS, the recovery process may last from several weeks up to 2 years. Prevention of thyroid cancer must be a priority. All children and pregnant women must be offered potassium iodide to protect the thyroid from the uptake of radioactive iodine.

Acute Radiation Syndrome Emerging Drugs Chapters

This segment of the Acute Radiation Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute Radiation Syndrome Emerging Drugs

- HemaMax: Neumedicines

HemaMax™ is based on recombinant human interleukin-12 (IL-12) and is a broad-spectrum biologic therapy. IL-12 is a heterodimeric cytokine that has been shown to play an essential role in regulating inflammatory responses, including an innate resistance to infection and an ability to stimulate the production of interferon-gamma from natural killer cells, macrophages and T-cells. IL-12 also has shown resistance to many pathogens and to transplantable and chemically induced tumors.

- Recilisib: Onconova Therapeutics

Recilisib is a protein kinase inhibitor based small molecule with radiation protection properties. It addresses the need for medical countermeasures to treat the effects of acute radiation syndromes (ARS), specifically radiation-induced cytopenia. Recilisib employs a novel mechanism of action that involves intracellular signaling and DNA damage repair pathways. In pre-clinical studies, cells treated with Recilisib sustained less DNA damage upon exposure to ionizing radiation in comparison to untreated cells.

Further product details are provided in the report……..

Acute Radiation Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Acute Radiation Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players in Acute Radiation Syndrome

There are approx. 10+ key companies which are developing the therapies for Acute Radiation Syndrome. The companies which have their Acute Radiation Syndrome drug candidates in the most advanced stage, i.e. phase II include, HemaMax.

- Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

- Route of Administration

Acute Radiation Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Oral

- Parenteral

- intravitreal

- Subretinal

- Topical.

- Molecule Type

Products have been categorized under various Molecule types such as

- Monoclonal Antibody

- Peptides

- Polymer

- Small molecule

- Gene therapy

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute Radiation Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Radiation Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Radiation Syndrome drugs.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence Acute Radiation Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Acute Radiation Syndrome.

- In May 2020, Cellphire, announced that the U.S. Food and Drug Administration (FDA) has granted an orphan drug designation for its platelet-based freeze-dried hemostatic, Thrombosomes®, for treatment of acute radiation syndrome (ARS).

Acute Radiation Syndrome Report Insights

- Acute Radiation Syndrome Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Acute Radiation Syndrome Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Acute Radiation Syndrome drugs?

- How many Acute Radiation Syndrome drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Radiation Syndrome?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute Radiation Syndrome therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for Acute Radiation Syndrome and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- Onconova Therapeutics

- Neumedicines

- Meabco

- Pluristem Therapeutics

- Valenta Pharmaceuticals

- Humanetics Corporation

- Abion

- Cleveland BioLabs

- Cellphire

- Chrysalis BioTherapeutics

- iNtRON Biotechnology

Key Products

- Recilisib

- HemaMax

- BP-C2

- PLX R18

- Myelo 001

- BIO-300

- ABN-601

- Entolimod

- Thrombosomes

- TP508

- KMRC011

Acute Radiation Syndrome - Pipeline Insight, 2020

Table of Contents

Introduction
Executive Summary
Acute Radiation Syndrome: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Acute Radiation Syndrome - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
• Acute Radiation Syndrome companies' collaborations, Licensing, Acquisition -Deal Value Trends
Acute Radiation Syndrome Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
• Comparative Analysis
HemaMax: Neumedicines
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
BIO 300: Humanetics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
BP-C2: Meabco
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Acute Radiation Syndrome Key Companies
Acute Radiation Syndrome Key Products
Acute Radiation Syndrome- Unmet Needs
Acute Radiation Syndrome- Market Drivers and Barriers
Acute Radiation Syndrome- Future Perspectives and Conclusion
Acute Radiation Syndrome Analyst Views
Acute Radiation Syndrome Key Companies
Appendix


List of Tables

Table 1 Total Products for Acute Radiation Syndrome
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products


List of Figures

Figure 1 Total Products for Acute Radiation Syndrome
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • Global Recombinant Human Erythropoietin (rhEPO) Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 99
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - ESRD - Cancer - HIV - Wounds and Neural Disease Segment by Application - Hospi......
  • Global rhEPO Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 97
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - ESRD - Cancer - HIV - Wounds and neural disease Segment by Application - Hospi......
  • Global Rhematoid Arthritis Drugs Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 94
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Pharmaceuticals - Biopharmaceuticals Segment by Application - Prescription - OTC......
  • Global Chronic Obstructive Pulmonary Disease Drugs Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 118
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Inhalers - Nebulizers Segment by Application - Emphysema - Chronic Bronchitis ......
  • Global Chronic Lymphocytic Leukemia Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 121
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Acutemyeloid (ormyelogenous)leukemia (AML) - Chronicmyeloid (ormyelogenous)leukemia (CML) - Acutelymphocyti......
  • Global Chemotherapy-induced Nausea and Vomiting Drugs Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 93
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - 5-HT3 Inhibitors - NK1 Inhibitors - Other Segment by Application - Highly Emetogenic ......
  • Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 120
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Aloxi (Palonosetron) - Kytril Generic (Granisetron) - Emend (Aprepitant) - Akynzeo (Netupitant-Palon......
  • Global ß-blockers Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 122
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Nonselective Agents - Selective Agents Segment by Application - Abnormal Heart Rhythms......
  • Global a-adrenoreceptor Antagonists Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 116
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Non-selective Antagonists - Selective Antagonists Segment by Application - Hypertension......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs